About Abgenix
Abgenix is a company based in Fremont (United States) founded in 1996 was acquired by Amgen in December 2005. Abgenix has completed 1 acquisition, including ImmGenics Pharmaceuticals. Abgenix offers products and services including Pancreatic Cancer Drugs, Zika Virus Vaccines, and Cancer Treatments. Abgenix operates in a competitive market with competitors including BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and Mereo BioPharma, among others.
- Headquarter Fremont, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Amgen
(Dec 14, 2005)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Abgenix
Abgenix offers a comprehensive portfolio of products and services, including Pancreatic Cancer Drugs, Zika Virus Vaccines, and Cancer Treatments.
Drugs that block growth of pancreatic cancer cells
Vaccines aimed at fighting Zika virus infections
Treatments for various cancers including pancreatic types
Funding Insights of Abgenix
Detailed funding history for Abgenix
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Abgenix
Abgenix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceutical products for treating multiple diseases
|
Locked | Locked | Locked |
Investor details for Abgenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abgenix
Abgenix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ImmGenics Pharmaceuticals.
Investment portfolio details for Abgenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Technology for antibody drug discovery.
|
Locked | Locked | 1993 | Locked |
Complete acquisition details for Abgenix
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Abgenix
Detailed financials for Abgenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abgenix Comparisons
Peer comparison for Abgenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Abgenix
Abgenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, Regeneron Pharmaceuticals and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
Detailed competitors of Abgenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abgenix
Complete news archive for Abgenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abgenix
Abgenix was founded in 1996.
Abgenix is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
Abgenix was a biopharmaceutical company focused on the discovery of fully human therapeutic antibodies for cancer and inflammatory diseases. Its products include Panitumumab, co-developed by Amgen is an IgG2 MAb which targets the epidermal growth factor receptor (EGFr), a protein that plays a role in cancer cell signaling. Its other product Denosumab is designed to target RANK Ligand, a protein that acts as the primary signal to promote bone removal. It claims to have potential in the treatment of a broad range of bone loss conditions including osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and rheumatoid arthritis. In December 2005, Amgen acquired Abgenix for around 2.2B.
Abgenix's top competitors include Moderna, BeiGene and Strand Therapeutics.
Abgenix offers Pancreatic Cancer Drugs, Zika Virus Vaccines, and Cancer Treatments.
Abgenix has made 1 acquisition, including ImmGenics Pharmaceuticals.
Abgenix has 1 investor. Key investors include Amgen.